FUROXONE
LOE ApproachingNDAORALSUSPENSION
Approved
Jan 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FUROXONE is an oral suspension small-molecule drug approved in 1958 by Takeda with unknown mechanism of action and indication profile. The exact therapeutic class and patient population are not currently specified in available data.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30), indicating a mature brand likely in harvest/transition phase with lean operational teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With 849 linked job opportunities, FUROXONE represents a mature product requiring operational, IT, and compliance-focused talent rather than commercial growth roles. Career movement on this product skews toward process excellence, legal/regulatory stewardship, and infrastructure management.
Rare Disease Business ManagerDirector
Worked on FUROXONE at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.